Achieve Life Sciences (ACHV) Cash & Equivalents (2010 - 2026)

Achieve Life Sciences' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $29.3 million for Q1 2026.

• Quarterly Cash & Equivalents rose 125.11% year-over-year to $29.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.3 million (up 125.11% YoY) and the FY2025 annual result came in at $36.4 million, up 185.42% from the prior year.
• Cash & Equivalents was $29.3 million for Q1 2026 at Achieve Life Sciences, down from $36.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $66.4 million in Q1 2024 and bottomed at $9.5 million in Q3 2024.
• A 5-year average of $27.2 million and a median of $24.8 million in 2022 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 403.98% in 2025, while the deepest fall reached 80.4% in 2025.
• Achieve Life Sciences' Cash & Equivalents stood at $24.8 million in 2022, then plunged by 42.46% to $14.3 million in 2023, then fell by 10.52% to $12.8 million in 2024, then surged by 185.42% to $36.4 million in 2025, then declined by 19.51% to $29.3 million in 2026.
• Business Quant data shows ACHV's Cash & Equivalents at $29.3 million in Q1 2026, $36.4 million in Q4 2025, and $48.1 million in Q3 2025.